about
Wnt-4 signaling is involved in the control of smooth muscle cell fate via Bmp-4 in the medullary stroma of the developing kidneyInduction of ureter branching as a response to Wnt-2b signaling during early kidney organogenesisGeneration of an allele to inactivate Wnt4 gene function conditionally in the mouseFemale mice expressing constitutively active mutants of FSH receptor present with a phenotype of premature follicle depletion and estrogen excessRegulated expression of putative membrane progestin receptor homologues in human endometrium and gestational tissues.Wnts and the female reproductive system.Animal models for aberrations of gonadotropin action.Structural and functional analysis of rare missense mutations in human chorionic gonadotrophin β-subunit.Adrenal hyperplasia and tumours in mice in connection with aberrant pituitary-gonadal function.Mouse models of altered gonadotrophin action: insight into male reproductive disorders.Regulation of oestrogen action: role of 17 beta-hydroxysteroid dehydrogenases.Site-directed mutagenesis of the putative active site of human 17 beta-hydroxysteroid dehydrogenase type 1.First birth achieved after in vitro maturation of oocytes from a woman endowed with multiple antral follicles unresponsive to follicle-stimulating hormone.Expression of 3beta-hydroxysteroid dehydrogenase type 1, P450 aromatase, and 17beta-hydroxysteroid dehydrogenase types 1, 2, 5 and 7 mRNAs in human early and mid-gestation placentas.The partial female to male sex reversal in Wnt-4-deficient females involves induced expression of testosterone biosynthetic genes and testosterone production, and depends on androgen action.Characterization of rat 17 beta-hydroxysteroid dehydrogenase type 1 gene and mRNA transcripts.Patterning parameters associated with the branching of the ureteric bud regulated by epithelial-mesenchymal interactions.Constitutively active follicle-stimulating hormone receptor enables androgen-independent spermatogenesis.Role of Follicle-Stimulating Hormone in SpermatogenesisImmunological measurement of human 17 beta-hydroxysteroid dehydrogenaseA point mutation in the putative TATA box, detected in nondiseased individuals and patients with hereditary breast cancer, decreases promoter activity of the 17 beta-hydroxysteroid dehydrogenase type 1 gene 2 (EDH17B2) in vitroRetinoic acids increase 17 beta-hydroxysteroid dehydrogenase type 1 expression in JEG-3 and T47D cells, but the stimulation is potentiated by epidermal growth factor, 12-O-tetradecanoylphorbol-13-acetate, and cyclic adenosine 3',5'-monophosphate onlExpression of mouse 17beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase type 7 in the ovary, uterus, and placenta: localization from implantation to late pregnancyThe proximal promoter region of the gene encoding human 17beta-hydroxysteroid dehydrogenase type 1 contains GATA, AP-2, and Sp1 response elements: analysis of promoter function in choriocarcinoma cellsRegulation of estrogen action: role of 17 beta-hydroxysteroid dehydrogenasesIdentification of essential subelements in the hHSD17B1 enhancer: difference in function of the enhancer and that of the hHSD17BP1 analog is due to -480C and -486GTumor suppressor MCPH1 regulates gene expression profiles related to malignant conversion and chromosomal assembly
P50
Q28302685-6D027DC9-DAF2-432D-897F-FBF7DE141EE6Q28506528-5272DD9E-20C2-4440-BF3E-475BE28074C9Q28507132-780C2272-3CE8-431E-A8E9-507063EAEC6DQ33775566-440FCBF7-4767-4061-A978-77FD29D2A293Q34458285-5B423130-4B36-4BB2-963D-3D41DDE04C8BQ34465737-1F327B48-E967-401B-BD2C-EB0306CF93B7Q35523514-114BA55E-1CB8-4F1A-AD81-4E8C01C28455Q36075459-D26CC307-6D4D-4D57-B71E-113EFD7F7FA6Q37325139-324EEA65-06B4-4FD6-97C3-FF1F5B34E050Q38230314-2DD115A4-4887-4026-B009-62100D24D552Q40999887-3099EC38-4D88-45D9-A39C-CAFD5C61018BQ42830420-E95DF6AB-8BEE-4A8F-93E1-11D99D8D93ABQ45775863-9F1BD5B2-F3A0-4940-9563-F27862471F14Q46454716-721F7353-6DE6-4D37-BD40-1EADC88F9C65Q46525208-E6FA4933-09D3-486C-BE1B-606946A245BBQ48039231-C0A3D2B8-EAF2-40DF-BD99-4E7DB537BEFFQ52107652-03E786BC-0E39-4CB1-AD89-7345301BE614Q52628084-5DC3541B-9451-44A9-B86D-7A0F98042EBAQ60954827-0FFFA2EB-28AD-43F2-A2C1-96B571594288Q68480658-C9223B4D-D4DF-46C0-8ADE-26D80A58C07DQ72427562-D78F0397-5AD4-409D-BE1B-09EF02AFAED9Q73106844-258BA65F-D4C8-4E54-82E3-C7B490A097F3Q73392843-51E19264-9E63-4428-85E4-70991EF3C7E1Q73532013-4A0C4A97-B8D6-4B13-97F5-2D13587A1CCAQ78017204-01BE160A-BA3D-4619-A505-C974DC0060B0Q78086419-D88B1546-A85E-4CB2-A4D0-242342D3E739Q91951419-11542916-9D5A-41D1-BF7B-FF97E6E82208
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hellevi Peltoketo
@ast
Hellevi Peltoketo
@en
Hellevi Peltoketo
@es
Hellevi Peltoketo
@nl
Hellevi Peltoketo
@sl
type
label
Hellevi Peltoketo
@ast
Hellevi Peltoketo
@en
Hellevi Peltoketo
@es
Hellevi Peltoketo
@nl
Hellevi Peltoketo
@sl
prefLabel
Hellevi Peltoketo
@ast
Hellevi Peltoketo
@en
Hellevi Peltoketo
@es
Hellevi Peltoketo
@nl
Hellevi Peltoketo
@sl
P106
P31
P496
0000-0003-4019-0091